TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04742998

Intervention type: OTHER
Intervention: Acoustic-phonetic decoding task (DAP)
Description: Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
Study: NCT05251649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS combined with 40 Hz sound stimulation
Description: The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off.
Study: NCT05766852

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Somatic Psychoeducational Intervention
Description: Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatic Psychoeducational Intervention
Description: Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
Study: NCT05666609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of non-cutting seton (silicone)
Description: Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of non-cutting seton (silicone)
Description: Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
Study: NCT06199154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
Study: NCT06558513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW5004 tablets
Description: XNW5004 an EZH2 inhibitor, BID, administered in continuous
Study: NCT05672888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: 100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (given as two placebo tablets) administered orally BID with best available treatment.
Study: NCT05128682

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urodynamic testing with and without pudendal nerve stimulation
Description: A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
Study: NCT06165666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Approach by functional objectives
Description: The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol
Description: The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
Study: NCT05251649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40 Hz sound stimulation
Description: Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
Study: NCT05971095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation using the EPTE® Bipolar System device
Description: The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied in order to produce potentiation of the non-nociceptive pathway, using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts. Adjustments to amplitude and pulse width are made until the patient experiences paresthesias at a perceptible but not painful intensity, and the intensity will be set 200 μA above the detection threshold for each subject.~In order to depress the nociceptive pathway, the low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to. To ensure the recruitment of higher threshold type C nociceptive fibers, the intensity level will be programmed at the pain threshold for each subject.
Study: NCT05738330

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Monitoring on Renal Replacement Therapy - Hemodialysis (SMaRRT-HD)
Description: Dialysis clinics randomized to the SMaRRT-HD group will use the SMaRRT-HD system to capture patient-reported symptoms and support clinician follow-up. The online system includes the patient symptom ePROM surveys, clinician real-time email alerts, clinician guidances for symptom management, and patient-facing symptom reports as well as an administrative dashboard supporting management of trial participants at clinics using SMaRRT-HD. Designated clinic personnel (i.e., patient care technicians and nurses) will receive training on how to use the system to administer the symptom ePROM surveys to patients on tablet computers. Designated clinic nurses and medical providers will receive training on how to access guidances for symptom management and patient-facing symptom reports in the SMaRRT-HD system. For trial participants in SMaRRT-HD clinics, the SMaRRT-HD system will be implemented in addition to the Usual Care approach to symptom monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Dialysis clinics randomized to Usual Care will not adopt SMaRRT-HD or any other trial-driven procedures. Usual Care clinics will monitor symptoms through clinical care interactions with participants and by administering a CMS-mandated Health-Related Quality of Life (HRQOL) survey that includes questions about symptoms.
Study: NCT04778592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX-018810
Description: Study Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06447909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment App
Description: The behavioral treatment app content consists of tasks that caregivers can assign to their children in the app (e.g., finish homework, make bed, etc.). These tasks are completed offline, and then caregivers approve the child's completion of those tasks through the app, administering a token reward (coins) in-app. In the child version of the app, children take care of a virtual pet by feeding, cleaning, buying various accessories (using in-game coins), and exploring different lands with the virtual pet. The caregiver-assigned token coins can be used to redeem items needed to raise their pet, and access virtual lands. Caregivers can also choose to have their child redeem virtual tokens for real-life rewards. Ultimately, the app combines a video game with evidence-based principles to help children practice important tasks and behaviors as administered by caregivers.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham app
Description: As described above, the child will access a virtual pet that they can feed, clean and buy various accessories by redeeming virtual coins. They will not be able to explore different lands with that pet. Coins in the placebo version will be rewarded non-contingently. Additionally, children will not be able to redeem coins for real-life rewards as above in the treatment app. Caregivers will not need to review and approve tasks in order to redeem coins. The caregiver-version of the app will not contain the Assigned or Review tabs as assigned above, since the child will earn coins regardless of whether or not they complete tasks, so caregivers will not be able to review nor assign tasks. Instead, caregivers in this group will only have access to the guide tab which will contain helpful articles the parent can read about disruptive behavior problems in children.
Study: NCT04694781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN6051
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN6051
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN6051
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN6051
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Study: NCT04313465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate discharge
Description: Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
Study: NCT04477616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 7 regimen
Description: patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 regimen
Description: patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
Study: NCT05020574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Given orally (PO)
Study: NCT05719116

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.
Study: NCT04949009

Intervention type: DRUG
Intervention: Avatrombopag
Description: Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
Study: NCT05024513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin and 5-fluorouracil
Description: Intra-arterial chemotherapy consisted of Oxaliplatin (40mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for22 hours) on days 1-3 every 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary Drainage
Description: External biliary drainage, or biliary stent placement; Biliary stent placement plus Iodine-125 seed strands is allowed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Nutrition support, symptomatic treatment, and other supportive treatments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External biliary drainage
Description: External biliary drainage
Study: NCT06477783

Intervention type: DRUG
Intervention: Teclistamab
Description: Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
Study: NCT05870345

Intervention type: DEVICE
Group type: OTHER
Intervention: Butterfly IQ
Description: Butterfly IQ is a pocket sized ultrasound device. Each participant will undergo a ultrasound exam of both elbows using a pocket sized ultrasound device.
Study: NCT05836285

Intervention type: OTHER
Intervention: ARRC
Description: Eligible for ARRC and managed in ARRC unit

Intervention type: OTHER
Intervention: Usual Care
Description: Eligible for ARRC but managed elsewhere as no ARRC bed available
Study: NCT06279611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY007
Description: FC and LY007 infusion
Study: NCT06157034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inert Material

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zingier officinale powder
Description: The raw form of Zingiber officinale will be grounded in powder by manual grinding and will be encapsulated.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carum carvi, L powder
Description: The raw form of Carum carvi, L will be grounded in powder by manual grinding and will be encapsulated.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mentha spicata oil
Description: Mentha spicata L will be extracted in the form of oil and will be encapsulated.
Study: NCT04694781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
Study: NCT05670405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Trauma PORTAL
Description: Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R\&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R\&R.
Study: NCT05348811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC combined with donafenib and sintilimab
Description: HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol.
Study: NCT05317130

Intervention type: OTHER
Intervention: Athlete health monitoring
Description: Observational study
Study: NCT05653583

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wrist Device
Description: peripheral nerve stimulation via wrist-worn device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ear Device
Description: peripheral nerve stimulation via ear-worn device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Wrist-worn device that does not actually deliver stimulation
Study: NCT06070987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BoNT-A injections
Description: Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 100 units. The dose range of each target muscle is as below:100 units in rectus femoris.
Study: NCT05830188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping and Resilience Intervention for Adolescents
Description: It is a school-based resilience enhancement program to help adolescents build skills of positive coping and social support to minimize negative coping and distress by sharing, identifying, and discussing their feelings, thoughts, and actions regarding problems and stressful events.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printing materials of Coping and Resilience Intervention for Adolescents
Description: Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group.
Study: NCT06070987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BoNT-A injection and robot therapy
Description: Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot after BoNT-A injected in the affected rectus femoris, then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: None BoNT-A injection and robot therapy
Description: Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot (do not inject BoNT-A in the affected rectus femoris), then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs.
Study: NCT04648124

Intervention type: DEVICE
Intervention: IRMf-r (séquence resting state)
Description: Functional MRI of functional brain networks

Intervention type: DEVICE
Intervention: IRMf-r (séquence resting state)
Description: Functional MRI of functional brain networks

Intervention type: DEVICE
Intervention: IRMf-r (séquence resting state)
Description: Functional MRI of functional brain networks